Search

A new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia

Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Meet Helen Papadaki, our January volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…

Read more

Meet Helen Papadaki, our January volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more

Meet Ton Hagenbeek, our May volunteer of the month

Anton Hagenbeek began as EHA Volunteer when EHA was only starting out. Below you will read more about his motivations and invites fresh blood to support the organization.

Read more